Product Description
Amiodarone is used to treat life-threatening heart rhythm problems called ventricular arrhythmias. This medicine is used in patients who have already been treated with other medicines that did not work well. (Sourced from: https://www.mayoclinic.org/drugs-supplements/amiodarone-oral-route/description/drg-20061854)
Mechanisms of Action: CYP3A Inhibitor, CYP2D6 Inhibitor, CYP2C9 Inhibitor, CYP1A2 Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral, Intravenous
FDA Designation: *
Approval Status: Approved
Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: None
Company: Sanofi
Company Location: Europe
Company Founding Year: 1973
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Greece, United States
Active Clinical Trial Count: 3
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Atrial Fibrillation|Coronary Artery Disease|Ventricular Fibrillation
Phase 1: Kidney Diseases|Polycystic Kidney, Autosomal Dominant
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT07181265 |
JMKX003142-103 | P1 |
Not yet recruiting |
Kidney Diseases|Polycystic Kidney, Autosomal Dominant |
2026-04-30 |
2025-09-19 |
Primary Endpoints |
|
NCT06730828 |
AMIOMEND | P2 |
Recruiting |
Atrial Fibrillation |
2025-11-01 |
2024-12-13 |
Primary Endpoints|Treatments |
|
2024-519233-33-00 |
FLECA-ED | P3 |
Recruiting |
Coronary Artery Disease|Ventricular Fibrillation|Atrial Fibrillation |
2025-06-30 |
2025-05-02 |
Treatments |